Abstracts tagged "Macrophage"

Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 1767 • 2015 ACR/ARHP Annual Meeting
Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity
Sebastian Braehler¹, Dongyue Huang², Matthew Cheung², Walter Akers³ and Alfred Kim², ¹Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, ²Rheumatology, Washington University School of Medicine, Saint Louis, MO, ³Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Glomerulonephritis (GN) represents a major cause of morbidity & mortality. The standard for diagnosing GN is through renal biopsy, but this is not performed…
Abstract Number: 1778 • 2015 ACR/ARHP Annual Meeting
Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis
Jeffrey Hampton¹, Nicholas A. Young², Sudha Agarwal³, Saba Aqel³, Kendra Jones³, Lai-Chu Wu^2,4, Nicole Powell⁵, John Sheridan⁵, Michael Bruss³ and Wael N. Jarjour², ¹Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Biological Chemistry and Pharmacology, The Ohio State University College of Medicine, Columbus, OH, ⁵Institute for Behavioral Medicine Research, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Chronic inflammation is pathognomonic of autoimmune diseases and contributes to organ damage. Our group has previously shown that moderate daily exercise reduces systemic inflammation…
Abstract Number: 2135 • 2015 ACR/ARHP Annual Meeting
miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation
Florian M.P. Meier¹, Derek S. Gilchrist¹, Derek Baxter², Diane Vaughan¹, Margaret Mullin³, David W. McCarey⁴, Pawel Herzyk⁵, Julie Galbraith⁵, Donna McIntyre¹, Russka Shumnalieva⁶, Ulf Müller-Ladner⁷, Iain B. McInnes⁸ and Mariola Kurowska-Stolarska¹, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology, University Hospital Ayr, Ayr, United Kingdom, ³School of Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁵Polyomics Facility, Institute of Molecular Cell and Systems Biology, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Internal Medicine, Clinic of Rheumatology, Sofia, Bulgaria, ⁷Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁸Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Recently, it was shown that extracellular vesicles (EV) convey microRNAs (miR) from platelets to endothelial cells1and regulate recipient cell gene expression. Interaction of synovial…
Abstract Number: 2548 • 2015 ACR/ARHP Annual Meeting
M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes
Philip J. Homan¹, Alexander Misharin¹, Carla Cuda², Salina Dominguez², Rana Saber², Fu-Nien Tsai³ and Harris R. Perlman⁴, ¹Medicine-Rheumatology, Northwestern University, Chicago, IL, ²Northwestern University, Chicago, IL, ³Medicine, Rhuematology, Northwestern University, Chicago, IL, ⁴Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Colony-stimulating factors (CSF) are simply defined as haemotopoitec growth factors. However, CSFs have been implicated to have additional functions in various autoimmune diseases. Specifically…
Abstract Number: 2569 • 2015 ACR/ARHP Annual Meeting
Regulation of SIRT1 Maybe a Perfect Strategy in Treatment of Rheumatoid Arthritis
Sang-Yeob Lee¹, Sung Won Lee², Won Tae Chung², Jae Ho Bae³, So Youn Park⁴ and Chi Dae Kim⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea, ²Rheumatology, Dong-A University Hospital, Busan, South Korea, ³Biochemistry, Pusan national university, Yong -San, South Korea, ⁴Medical Research Center for Ischemic Tissue Regeneration, Pusan national university, Yong -San, South Korea
Background/Purpose: Monocyte may differentiate to osteoclasts in bone and macrophages in joint. so, blocking of monocyte differentiation maybe effective target in RA (rheumatoid arthritis) treatment.…
Abstract Number: 2749 • 2015 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Lei Zhou¹, Robert Sikorski¹, Seema Rogers¹, Stefan Costin², Mariusz Korkosz³, Maria Jaraczewska-Baumann⁴, Péterfai Éva⁵, Bernadette Rojkovich⁶, Janos Bartalos⁷, Emma Masteller¹, Hong Xiang¹, Brian Wong¹ and Julie Hambleton¹, ¹Five Prime Therapeutics, Inc., South San Francisco, CA, ²PRA Heath Sciences, Berlin, Germany, ³Malopolskie Centrum Medyczne, The University Hospital in Krakow, Krakow, Poland, ⁴MedPolonia Sp. z o.o, Poznan, Poland, ⁵Drug Research Center, Balatonfüred, Hungary, ⁶Hospitaller Brothers of St. John of God, Budapest, Hungary, ⁷PRA Hungary Ltd, Budapest, Hungary
Background/Purpose: FPA008 is a humanized IgG4 anti-CSF1R antibody that blocks the binding of CSF1 and IL34 ligands to CSF1R, resulting in inhibition of the activation…
Abstract Number: 3003 • 2014 ACR/ARHP Annual Meeting
Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells
Tetsuo Toyama¹, Yoshihide Asano¹, Takehiro Takahashi¹, Ryosuke Saigusa¹, Yohei Ichimura¹, Takashi Taniguchi¹, Shinji Noda¹, Kaname Akamata¹, Shinichi Sato¹, Takafumi Kadono¹ and Koichi Shudo², ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Reseach Foundation ITSUU Laboratory, Tokyo, Japan
Background/Purpose: Am80 is a synthetic retinoid serving as an agonist for retinoic acid receptor α/β with chemical and pharmacological advantages over all-trans retinoic acid, such…
Abstract Number: 2952 • 2014 ACR/ARHP Annual Meeting
S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium
Peter L. van Lent¹, Rik Schelbergen², Arjen B. Blom¹, Tomas Leanderson³, Helena Eriksson⁴ and Wim B. van den Berg⁵, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Radboud university medical center, Nijmegen, Netherlands, ³Immunology Group, Lund University, Lund, Sweden, ⁴BioScience, Active Biotech AB, Lund, Sweden, ⁵Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Synovial activation is present in more than 50% of osteoarthritis (OA) patients and it is thought to be involved in the development of OA…
Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting
Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission
Y.Y.J. Gent¹, M.M. ter Wee¹, D den Uyl¹, N. Ahmadi², W.F. Lems³, O.S. Hoekstra⁴, A.E. Voskuyl¹ and C.J. Van der Laken³, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Radiology, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁴Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
Abstract Number: 1714 • 2014 ACR/ARHP Annual Meeting
IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma
Rebecca Alade, Shiwen Xu, Korsa Khan, Angela Tam, Christopher P. Denton and Voon H. Ong, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose IL6 is a key mediator in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear…
Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting
Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis
Naotake Tsuboi¹, Nobuhide Endo¹, Seiichi Matsuo² and Shoichi Maruyama¹, ¹Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…
Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRÃ¡
Iain B. McInnes¹, Gerd Burmester², Joel M. Kremer³, Pedro Miranda⁴, Mariusz Korkosz⁵, Jiri Vencovsky⁶, Andrea Rubbert-Roth⁷, Eduardo Mysler⁸, David Close⁹, Matthew A. Sleeman¹⁰, Alex Godwood¹¹, Sara Sandbach¹², Patricia C. Ryan¹³, Dominic Sinibaldi¹⁴, Wendy White¹³, Nadine A. Defranoux¹⁵ and Michael Weinblatt¹⁶, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁴Centro de Estudios Reumatologicos, Santiago, Chile, ⁵Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, ⁶Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, ⁷Med Clinic I, University of Cologne, koln, Germany, ⁸Rheumatology, OMI, Buenos Aires, Argentina, ⁹Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ¹⁰Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ¹¹Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ¹²Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, ¹³Translational Sciences, MedImmune, Gaithersburg, MD, ¹⁴R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, ¹⁵Crescendo Bioscience Inc., South San Francisco, CA, ¹⁶Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Julie Hambleton¹, Lei Zhou¹, Seema Rogers¹, Sjoerd van Marle², Thijs van Iersel², James Zanghi¹, Emma Masteller¹, Kevin Baker¹ and Brian Wong¹, ¹Five Prime Therapeutics, South San Francisco, CA, ²PRA Health Sciences, Groningen, Netherlands
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…
Abstract Number: 1209 • 2014 ACR/ARHP Annual Meeting
Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase
Hao Li^1,2, Qi Wu¹, PingAr Yang¹, Zheng Wang³, Jun Li¹, Bao Luo¹, Jeffrey C. Edberg¹, Hui-Chen Hsu¹, John D. Mountz^1,4 and Robert P. Kimberly on behalf of PROFILE investigators⁵, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, ⁴Birmingham VA Medical Center, Birmingham, AL, ⁵Clinical Immun & Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Ibrutinib, a Btk kinase activity inhibitor, is a novel inhibitor under development for autoimmune disease therapy. We have shown that Btk was significantly upregulated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].